373 related articles for article (PubMed ID: 25519989)
1. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
Chio CM; Lim CS; Bishop AC
Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
[TBL] [Abstract][Full Text] [Related]
2. Rational design of allosteric-inhibition sites in classical protein tyrosine phosphatases.
Chio CM; Yu X; Bishop AC
Bioorg Med Chem; 2015 Jun; 23(12):2828-38. PubMed ID: 25828055
[TBL] [Abstract][Full Text] [Related]
3. The Allosteric Site on SHP2's Protein Tyrosine Phosphatase Domain is Targetable with Druglike Small Molecules.
Marsh-Armstrong B; Fajnzylber JM; Korntner S; Plaman BA; Bishop AC
ACS Omega; 2018 Nov; 3(11):15763-15770. PubMed ID: 30533581
[TBL] [Abstract][Full Text] [Related]
4. Allosteric modulation of SHP2: Quest from known to unknown.
Wang N; Zhu S; Lv D; Wang Y; Khawar MB; Sun H
Drug Dev Res; 2023 Nov; 84(7):1395-1410. PubMed ID: 37583266
[TBL] [Abstract][Full Text] [Related]
5. Monobody Inhibitor Selective to the Phosphatase Domain of SHP2 and its Use as a Probe for Quantifying SHP2 Allosteric Regulation.
Sha F; Kurosawa K; Glasser E; Ketavarapu G; Albazzaz S; Koide A; Koide S
J Mol Biol; 2023 Apr; 435(8):168010. PubMed ID: 36806475
[TBL] [Abstract][Full Text] [Related]
6. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
7. Synthesis of small peptide compounds, molecular docking, and inhibitory activity evaluation against phosphatases PTP1B and SHP2.
Kostrzewa T; Sahu KK; Gorska-Ponikowska M; Tuszynski JA; Kuban-Jankowska A
Drug Des Devel Ther; 2018; 12():4139-4147. PubMed ID: 30584278
[TBL] [Abstract][Full Text] [Related]
8. Targeting a Pathogenic Cysteine Mutation: Discovery of a Specific Inhibitor of Y279C SHP2.
Kim JY; Plaman BA; Bishop AC
Biochemistry; 2020 Sep; 59(37):3498-3507. PubMed ID: 32871078
[TBL] [Abstract][Full Text] [Related]
9. Optimized allosteric inhibition of engineered protein tyrosine phosphatases with an expanded palette of biarsenical small molecules.
Korntner S; Pomorski A; Krężel A; Bishop AC
Bioorg Med Chem; 2018 May; 26(9):2610-2620. PubMed ID: 29673715
[TBL] [Abstract][Full Text] [Related]
10. Direct Chemical Activation of a Rationally Engineered Signaling Enzyme.
Chio CM; Cheng KW; Bishop AC
Chembiochem; 2015 Aug; 16(12):1735-9. PubMed ID: 26063205
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
12. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a potent and selective allosteric inhibitor targeting the SHP2 tunnel site for RTK-driven cancer treatment.
Luo R; Fu W; Shao J; Ma L; Shuai S; Xu Y; Jiang Z; Ye Z; Zheng L; Zheng L; Yu J; Zhang Y; Yin L; Tu L; Lv X; Li J; Liang G; Chen L
Eur J Med Chem; 2023 May; 253():115305. PubMed ID: 37023678
[TBL] [Abstract][Full Text] [Related]
14. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
15. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
16. The Landscape of Protein Tyrosine Phosphatase (Shp2) and Cancer.
Rehman AU; Rahman MU; Khan MT; Saud S; Liu H; Song D; Sultana P; Wadood A; Chen HF
Curr Pharm Des; 2018; 24(32):3767-3777. PubMed ID: 30398108
[TBL] [Abstract][Full Text] [Related]
17. SHP2-EGFR States in Dephosphorylation Can Inform Selective SHP2 Inhibitors, Dampening RasGAP Action.
Liu Y; Jang H; Nussinov R
J Phys Chem B; 2024 May; 128(21):5175-5187. PubMed ID: 38747619
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of SHP2 and SHP1 Protein Tyrosine Phosphatase Activity by Chemically Induced Dimerization.
Buck SJS; Plaman BA; Bishop AC
ACS Omega; 2022 Apr; 7(16):14180-14188. PubMed ID: 35559188
[TBL] [Abstract][Full Text] [Related]
19. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
Jin WY; Ma Y; Li WY; Li HL; Wang RL
Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
[TBL] [Abstract][Full Text] [Related]
20. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
